JFG
SAGE

Jefferies Financial Group’s Sage Therapeutics SAGE Stock Holding History

Jefferies Financial Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,000
Closed -$41.2K – 1953
2023
Q3 		$41.2K Buy
+2,000
New +$57.8K ﹤0.01% 1518

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jefferies Financial Group's SAGE Position: Q1 2025 in Review

Jefferies Financial Group sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 599,042 shares — an estimated $3.25M sold.

Jefferies Financial Group first reported a position in SAGE in Q4 2022 and held it in 7 quarters. The position peaked at $4.49M in Q3 2024. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Jefferies Financial Group reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jefferies Financial Group sold 599,042 Sage Therapeutics shares in Q1 2025, an estimated $3.25M.
  • Jefferies Financial Group first reported a position in Sage Therapeutics in Q4 2022 and held it in 7 quarters.
  • Jefferies Financial Group's Sage Therapeutics position peaked at $4.49M in Q3 2024.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Jefferies Financial Group's 13F filing for Q1 2025, filed 8 May 2025.